Skip to main content

Prodesse Gets FDA OK for H1N1 Claims for Assay

This article contains a clarification in the first graf regarding the claims for the ProFlu+ assay.

NEW YORK (GenomeWeb News) – Prodesse today said that the US Food and Drug Administration has cleared additional claims for the firm's ProFlu+ assay, which says that it correctly identifies as Influenza A positive specimens containing novel 2009 H1N1 influenza virus.

The Milwaukee, Wis.-based firm said in a statement that reactivity testing completed by the firm confirmed that the ProFlu+ test correctly identifies the Influenza A positive specimens containing novel 2009 H1N1 influenza virus. It noted that the testing was conducted on cultures of clinical isolates confirmed as 2009 H1N1 Influenza Virus using the CDC's real-time RT-PCR assay.

Prodesse also noted that its can distinguish between influenza A and B viruses, but it cannot differentiate influenza subtypes.

"Prodesse's recently completed reactivity testing confirms that our ProFlu+ test can be an important tool for health care professionals in the diagnoses of their patients, particularly during the Influenza A outbreak," Tom Shannon, president and CEO of Prodesse, said in a statement.

The ProFlu+ assay was initially cleared by FDA in January 2008 for the detection and discrimination of Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus.

Last month, FDA issued an Emergency Use Authorization for Focus Diagnostics' molecular assay for detecting the 2009 H1N1 flu virus.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.